Das Anti-IgLON5-Syndrom in der klinischen Neurologie – zwei Fallberichte

Johanna Niederschweiberer, Nicolas U Schumacher, Daniela Kumpfmüller, Charlotte Lingg, Simone Graf, Benno Ikenberg, Mark Mühlau, Paul Lingor, Bernhard Hemmer, Benjamin Knier2022 · DOI

Introduction

Anti-IgLON5 syndrome represents a unique frontier in neurology, bridging the gap between autoimmune encephalitis and neurodegenerative tauopathies. First described in 2014, this rare condition is characterized by the presence of antibodies against IgLON5, a cell adhesion molecule, alongside the pathological accumulation of hyperphosphorylated tau protein in the brainstem and hypothalamus. This paper details two clinical cases that underscore the syndrome's heterogeneous presentation and the vital role of early intervention.

The Diagnostic Challenge

The syndrome is often referred to as a "great mimic" because its clinical features overlap significantly with more common neurological and sleep disorders. Patients frequently present with:

  • Sleep-disordered breathing: Obstructive sleep apnea (OSAS) and stridor.
  • Parasomnias: REM-sleep behavior disorder (RBD) and non-REM parasomnias.
  • Bulbar dysfunction: Dysphagia, dysarthria, and vocal cord paresis.
  • Movement disorders: Gait instability, parkinsonism, or chorea.

Because these symptoms are non-specific, the diagnosis is often delayed, which is critical given the potentially fatal nature of the disease if left untreated.

Case Presentations

Case 1: Acute Bulbar Failure and Genetic Predisposition

A 79-year-old female presented with rapidly progressive bulbar symptoms, including severe swallowing difficulties and speech impairment, accompanied by muscle wasting that initially suggested Amyotrophic Lateral Sclerosis (ALS). The clinical course was complicated by life-threatening laryngospasms, necessitating emergency intubation and tracheotomy.

Diagnostic workup revealed anti-IgLON5 antibodies in both serum and cerebrospinal fluid (CSF). Genetic testing identified the HLA-DRB11001 and HLA-DQB10501 alleles, which are strongly associated with this syndrome. Following seven cycles of plasmapheresis and subsequent maintenance therapy with Rituximab, the patient showed significant stabilization and improvement in bulbar function.

Case 2: Fluctuating Ocular Symptoms

In contrast, a 62-year-old male presented with a more indolent course characterized by fluctuating double vision (diplopia) and chronic fatigue. Polysomnography confirmed severe obstructive sleep apnea. Despite the milder initial presentation, antibody testing confirmed the diagnosis of Anti-IgLON5 syndrome. This patient responded exceptionally well to oral Prednisolone; within one year, he was largely symptom-free, though his sleep apnea persisted, requiring continuous positive airway pressure (CPAP) therapy.

Pathophysiological Insights: Autoimmunity vs. Neurodegeneration

The dual nature of Anti-IgLON5 syndrome—autoimmune and neurodegenerative—poses a fascinating question: does the antibody cause the tauopathy, or are they independent processes? Current evidence suggests that the immune-mediated attack on the neuronal cytoskeleton likely triggers the subsequent neurodegenerative changes. The strong association with specific HLA alleles further supports a primary autoimmune etiology.

Treatment and Prognosis

There is currently no standardized treatment protocol, but immunotherapy is the cornerstone of management. Data suggests that 30–50% of patients respond to treatment, which may include:

  • High-dose corticosteroids.
  • Plasmapheresis or intravenous immunoglobulins (IVIG).
  • Long-term immunosuppression with Rituximab or Azathioprine.

The "point of no return"—the transition from a reversible autoimmune stage to irreversible neurodegeneration—remains a subject of intense study. Early diagnosis via antibody screening in patients with unexplained sleep-breathing disorders or brainstem syndromes is the most significant predictor of a positive clinical outcome.

Conclusion

Anti-IgLON5 syndrome is a critical differential diagnosis in complex neurological cases involving sleep and brainstem dysfunction. While the disease is rare, the potential for significant recovery with immunotherapy highlights the need for increased clinical awareness and early diagnostic testing.

Summary updated

BibTeX
@inproceedings{niederschweiberer2022das,
  author = {Johanna Niederschweiberer and Nicolas U Schumacher and Daniela Kumpfmüller and Charlotte Lingg and Simone Graf and Benno Ikenberg and Mark Mühlau and Paul Lingor and Bernhard Hemmer and Benjamin Knier},
  title = {{Das Anti-IgLON5-Syndrom in der klinischen Neurologie – zwei Fallberichte}},
  booktitle = {Der},
  year = {2022},
  doi = {10.1007/s00115-022-01344-9},
}
Figure